Advances in Anti-Dementia Therapies in Older Adults

Recent updates in dementia treatment include traditional medications (acetylcholinesterase inhibitors, memantine) now used off-label for vascular dementia, alongside newly approved amyloid-targeting monoclonal antibodies (lecanemab, donanemab) that show disease-modifying effects in early Alzheimer's disease but require careful monitoring for adverse effects. Non-pharmacological interventions such as regular exercise and multimodal lifestyle programs demonstrate cognitive benefits, while digital health applications and GLP-1 analogs show mixed or limited evidence.